Page last updated: 2024-12-06

sulforidazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sulforidazine: structure in Merck [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID31765
CHEMBL ID2107268
CHEBI ID135644
SCHEMBL ID145025
MeSH IDM0120916

Synonyms (56)

Synonym
tpn 12
brn 1230366
sulforidazinum [inn-latin]
sulforidazina [inn-spanish]
2-methylsulfonyl-10-(2-(1-methyl-2-piperidyl)ethyl)phenothiazin
psychoson
sulforidazine
phenothiazine, 10-(2-(1-methyl-2-piperidyl)ethyl)-2-methylsulfonyl-
tpn-12
imagotan
sulforidazine [inn:dcf]
10-(2-(1-methyl-2-piperidyl)ethyl)-2-methylsulfonylphenothiazine
inofal
solforidazina [dcit]
einecs 238-818-7
CHEBI:135644
L000789
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfonylphenothiazine
sulforidazina
14759-06-9
unii-b7599i244x
b7599i244x ,
solforidazina
sulforidazinum
cas_14759-06-9
nsc_31765
bdbm86723
thioridazine-2-sulfone
thioridazine sulphone
thioridazine sulfone
CHEMBL2107268
FT-0675190
(+/-)-thioridazine-2-sulfone
thioridazine 2-sulfone
thioridazine hydrochloride impurity e [ep impurity]
10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfonyl)-
103827-31-2
thioridazine impurity e [ep impurity]
2-methylsulfonyl-10-(2-(1-methyl-2-piperidyl)ethyl)phenothiazine
sulforidazine [who-dd]
phenothiazine, 10-(2-(1-methyl-2-piperidyl)ethyl)-2-(methylsulfonyl)-
sulforidazine [mi]
sulforidazine [inn]
sulforidazine [mart.]
10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfonyl)-10h-phenothiazine
SCHEMBL145025
10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfonyl)-10h-phenothiazine #
FLGCRGJDQJIJAW-UHFFFAOYSA-N
10-[2-(1-methyl-2-piperidinyl)ethyl]-2-methylsulfonylphenothiazine
10h-phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfonyl)-
2-methylsulfonyl-10-[2-(1-methyl-2-piperidyl)ethyl]phenothiazine
2-methanesulfonyl-10-[2-(1-methylpiperidin-2-yl)ethyl]-10h-phenothiazine
AKOS030239787
J-008369
Q7636215
DTXSID30864531

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"5 h) was administered to all the volunteers to investigate the effect of a slow rate of dosage input on the pharmacokinetic parameters of this drug."( Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
Chakraborty, BS; Choc, MG; Hawes, EM; Hubbard, JW; Korchinski, ED; McKay, G; Midha, KK; Robinson, WT, 1989
)
0.28
"The relationship between chronic oral dosage with a long-acting formulation of propranolol and plasma propranolol levels 22 to 23 hours later is described in 12 adult male patients with organic brain disease."( Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations.
Greendyke, RM; Kanter, DR, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenothiazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (59.09)18.7374
1990's7 (31.82)18.2507
2000's2 (9.09)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.39 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]